Vertex Pharmaceutic (VRTX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
| 12-2015 | 12-2014 | 12-2013 | 12-2012 | 12-2011 | |
| Cash Flows From Operating Activities | |||||
| Net Income | -588,181 | -742,745 | -687,550 | -51,135 | 41,179 |
| Depreciation Amortization | 62,343 | 63,257 | 48,365 | 38,191 | 35,041 |
| Income taxes - deferred | 3,283 | 281 | -285,053 | 36,660 | -7,501 |
| Accounts receivable | -110,098 | 7,428 | 53,363 | 39,912 | -170,606 |
| Accounts payable and accrued liabilities | -1,709 | 25,048 | -49,234 | 14,892 | 37,468 |
| Other Working Capital | -85,950 | -70,976 | -14,147 | -11,817 | -192,164 |
| Other Operating Activity | 354,880 | 144,595 | 873,590 | 201,138 | 400,318 |
| Operating Cash Flow | $-365,432 | $-573,112 | $-60,666 | $267,841 | $143,735 |
| Cash Flows From Investing Activities | |||||
| PPE Investments | -45,302 | -51,201 | -51,393 | -71,140 | -34,595 |
| Net Acquisitions | -80,000 | -10,000 | N/A | N/A | -60,000 |
| Purchase Of Investment | -633,041 | -1,424,172 | -2,410,720 | -1,706,655 | -721,728 |
| Sale Of Investment | 1,067,443 | 1,557,938 | 2,348,295 | 1,367,927 | 1,016,040 |
| Other Investing Activity | -40,244 | 9,444 | 1,257 | -15,949 | 12,695 |
| Investing Cash Flow | $268,856 | $82,009 | $-112,561 | $-425,817 | $212,412 |
| Cash Flows From Financing Activities | |||||
| Debt Issued | 23,662 | 294,243 | 0 | 0 | N/A |
| Debt Repayment | -19,954 | -21,443 | -16,215 | -2,615 | -155,000 |
| Common Stock Issued | 185,592 | 274,615 | 265,878 | 191,721 | 124,862 |
| Other Financing Activity | -381 | 1,824 | -1,252 | -16,902 | -94,100 |
| Financing Cash Flow | $188,919 | $549,239 | $248,411 | $172,204 | $-124,238 |
| Exchange Rate Effect | -2,834 | -2,176 | 4,708 | -141 | 214 |
| Beginning Cash Position | 625,259 | 569,299 | 489,407 | 475,320 | 243,197 |
| End Cash Position | 714,768 | 625,259 | 569,299 | 489,407 | 475,320 |
| Net Cash Flow | $89,509 | $55,960 | $79,892 | $14,087 | $232,123 |
| Free Cash Flow | |||||
| Operating Cash Flow | -365,432 | -573,112 | -60,666 | 267,841 | 143,735 |
| Capital Expenditure | -45,302 | -51,201 | -51,393 | -71,140 | -34,595 |
| Free Cash Flow | -410,734 | -624,313 | -112,059 | 196,701 | 109,140 |